Open Access

Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis

  • Authors:
    • Shiqun Wang
    • Lu Li
    • Long Shi
  • View Affiliations

  • Published online on: July 12, 2019     https://doi.org/10.3892/mmr.2019.10494
  • Pages: 2657-2666
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glycyrrhizic acid (GA) is primarily used as an anti‑inflammatory agent in cases of chronic hepatitis. However, its underlying mechanisms in diverse biological processes and its reported benefits are yet to be fully elucidated. In the current study, an analytical method based on pharmacogenomics was established to mine disease‑modulatory activities mediated by GA. Five primary protein targets and 138 functional partners were identified for GA by querying open‑source databases, including Drugbank and STRING. Subsequently, GA‑associated primary and secondary protein targets were integrated into Cytoscape to construct a protein‑protein interaction network to establish connectivity. GA‑associated target genes were then clustered based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The tumor necrosis factor axis was revealed to be a primary module regulated by GA‑associated targets. Furthermore, 12 hub genes were queried to assess their potential anti‑cancer effects using cBioPortal. The results indicated that pharmacogenomics‑based analysis improved understanding of the underlying drug‑target events of GA and provided predictive and definitive leads for future studies.

References

1 

Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH and Cheng YC: First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 73:373–380. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Ming LJ and Yin AC: Therapeutic effects of glycyrrhizic acid. Nat Prod Commun. 8:415–418. 2013.PubMed/NCBI

3 

Farrukh MR, Nissar UA, Kaiser PJ, Afnan Q, Sharma PR, Bhushan S and Tasduq SA: Glycyrrhizic acid (GA) inhibits reactive oxygen Species mediated photodamage by blocking ER stress and MAPK pathway in UV-B irradiated human skin fibroblasts. J Photochem Photobiol B. 148:351–357. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Fouladi S, Masjedi M, Ghasemi R, G Hakemi M and Eskandari N: The in vitro impact of glycyrrhizic acid on CD4+ T lymphocytes through OX40 receptor in the patients with allergic rhinitis. Inflammation. 41:1690–1701. 2018. View Article : Google Scholar : PubMed/NCBI

5 

He SQ, Gao M, Fu YF and Zhang YN: Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling. Int J Clin Exp Pathol. 8:5175–5181. 2015.PubMed/NCBI

6 

Hou S, Zhang T, Li Y, Guo F and Jin X: Glycyrrhizic acid prevents diabetic nephropathy by activating AMPK/SIRT1/PGC-1α signaling in db/db mice. J Diabetes Res. 2017:28659122017. View Article : Google Scholar : PubMed/NCBI

7 

Kiratipaiboon C, Tengamnuay P and Chanvorachote P: Glycyrrhizic acid attenuates stem cell-like phenotypes of human dermal papilla cells. Phytomedicine. 22:1269–1278. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Li C, Peng S, Liu X, Han C, Wang X, Jin T, Liu S, Wang W, Xie X, He X, et al: Glycyrrhizin, a direct HMGB1 antagonist, ameliorates inflammatory infiltration in a model of autoimmune thyroiditis via inhibition of TLR2-HMGB1 signaling. Thyroid. 27:722–731. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Lin SC, Chu PY, Liao WT, Wu MY, Tsui KH, Lin LT, Huang CH, Chen LL and Li CJ: Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway. Oncol Rep. 39:703–710. 2018.PubMed/NCBI

10 

Refahi S, Pourissa M, Zirak MR and Hadadi G: Modulation expression of tumor necrosis factor α in the radiation-induced lung injury by glycyrrhizic acid. J Med Phys. 40:95–101. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Wang LY, Cheng KC, Li Y, Niu CS, Cheng JT and Niu HS: Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 95:599–604. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Wang YM and Du GQ: Glycyrrhizic acid prevents enteritis through reduction of NF-κB p65 and p38MAPK expression in rat. Mol Med Rep. 13:3639–3646. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Yang J, Shi Y, Chen H, Wang X, Chen Y and Yang B: Glycyrrhizic acid attenuates myocardial injury: Involvement of RIP140/NF-κB Pathway. Biomed Pharmacother. 95:62–67. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Zhang H, Zhang R, Chen J, Shi M, Li W and Zhang X: High mobility group Box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats. Kidney Blood Press Res. 42:894–904. 2017. View Article : Google Scholar : PubMed/NCBI

15 

Relling MV and Evans WE: Pharmacogenomics in the clinic. Nature. 526:343–350. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Mooney SD: Progress towards the integration of pharmacogenomics in practice. Hum Genet. 134:459–465. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T, Compérat E, Spano JP and Malouf G: Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions. Bull Cancer. 104:789–799. 2017.(In French). View Article : Google Scholar : PubMed/NCBI

18 

Su G, Morris JH, Demchak B and Bader GD: Biological network exploration with Cytoscape 3. Curr Protoc Bioinformatics. 47:8.13.1–24. 2014. View Article : Google Scholar

19 

Guo Y, Bao Y, Ma M and Yang W: Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci. 18(pii): E7222017. View Article : Google Scholar : PubMed/NCBI

20 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI

21 

Canault B, Bourg S, Vayer P and Bonnet P: Comprehensive network map of ADME-Tox databases. Mol Inform. 36:2017. View Article : Google Scholar : PubMed/NCBI

22 

Coelho-Santos V, Leitão RA, Cardoso FL, Palmela I, Rito M, Barbosa M, Brito MA, Fontes-Ribeiro CA and Silva AP: The TNF-α/NF-κB signaling pathway has a key role in methamphetamine-induced blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 35:1260–1271. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Kang R, Xie Y, Zhang Q, Hou W, Jiang Q, Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, et al: Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res. 27:916–932. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Asl MN and Hosseinzadeh H: Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 22:709–724. 2008. View Article : Google Scholar : PubMed/NCBI

26 

Brumatti G, Salmanidis M and Ekert PG: Crossing paths: Interactions between the cell death machinery and growth factor survival signals. Cell Mol Life Sci. 67:1619–1630. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Hayden MS and Ghosh S: Regulation of NF-κB by TNF family cytokines. Semin Immunol. 26:253–266. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Yaw HP, Ton SH, Chin HF, Karim MK, Fernando HA and Kadir KA: Modulation of lipid metabolism in glycyrrhizic acid-treated rats fed on a high-calorie diet and exposed to short or long-term stress. Int J Physiol Pathophysiol Pharmacol. 7:61–75. 2015.PubMed/NCBI

29 

Chen S, Jiang S, Zheng W, Tu B, Liu S, Ruan H and Fan C: RelA/p65 inhibition prevents tendon adhesion by modulating inflammation, cell proliferation, and apoptosis. Cell Death Dis. 8:e27102017. View Article : Google Scholar : PubMed/NCBI

30 

Miot C, Imai K, Imai C, Mancini AJ, Kucuk ZY, Kawai T, Nishikomori R, Ito E, Pellier I, Dupuis Girod S, et al: Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood. 130:1456–1467. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: TRAF2 is a valuable prognostic biomarker in patients with prostate cancer. Med Sci Monit. 23:4192–4204. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Wei B, Ruan J, Mi Y, Hu J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: Knockdown of TNF receptor-associated factor 2 (TRAF2) modulates in vitro growth of TRAIL-treated prostate cancer cells. Biomed Pharmacother. 93:462–469. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Jin H, Dong YY, Zhang H, Cui Y, Xie K and Lou G: shRNA depletion of cIAP1 sensitizes human ovarian cancer cells to anticancer agent-induced apoptosis. Oncol Res. 22:167–176. 2014. View Article : Google Scholar : PubMed/NCBI

34 

Seidelin JB: Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis. Scand J Gastroenterol. 50 (Suppl 1):S1–S29. 2015. View Article : Google Scholar

35 

Hostetler BJ, Uchakina ON, Ban H and McKallip RJ: Treatment of hematological malignancies with glycyrrhizic acid. Anticancer Res. 37:997–1004. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Kim KJ, Choi JS, Kim KW and Jeong JW: The anti-angiogenic activities of glycyrrhizic acid in tumor progression. Phytother Res. 27:841–846. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Doss GP, Agoramoorthy G and Chakraborty C: TNF/TNFR: Drug target for autoimmune diseases and immune-mediated inflammatory diseases. Front Biosci (Landmark Ed). 19:1028–1040. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Berman-Booty LD and Knudsen KE: Models of neuroendocrine prostate cancer. Endocr Relat Cancer. 22:R33–R49. 2015. View Article : Google Scholar : PubMed/NCBI

39 

Guo R, Tu Y, Xie S, Liu XS, Song Y, Wang S, Chen X and Lu L: A role for receptor-interacting protein kinase-1 in neutrophil extracellular trap formation in patients with systemic lupus erythematosus: A preliminary study. Cell Physiol Biochem. 45:2317–2328. 2018. View Article : Google Scholar : PubMed/NCBI

40 

Ando K, Sakoda M, Ueno S, Hiwatashi K, Iino S, Minami K, Kawasaki Y, Hashiguchi M, Tanoue K, Mataki Y, et al: Clinical implication of the relationship between high mobility group Box-1 and tumor differentiation in hepatocellular carcinoma. Anticancer Res. 38:3411–3418. 2018. View Article : Google Scholar : PubMed/NCBI

41 

Zhang Y, Li L, Qi C, Hua S, Fei X, Gong F and Fang M: Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25. Biomed Pharmacother. 110:692–699. 2019. View Article : Google Scholar : PubMed/NCBI

42 

Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic J: The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 207:101–106. 2009. View Article : Google Scholar : PubMed/NCBI

43 

Shin MS, Kang Y, Wahl ER, Park HJ, Lazova R, Leng L, Mamula M, Krishnaswamy S, Bucala R and Kang I: Macrophage migration inhibitory factor regulates U1 small nuclear RNP immune complex-mediated activation of the NLRP3 inflammasome. Arthritis Rheumatol. 71:109–120. 2019. View Article : Google Scholar : PubMed/NCBI

44 

Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M and Papaluca-Amati M: Pharmacogenomic information in drug labels: European medicines agency perspective. Pharmacogenomics J. 15:201–210. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, S., Li, L., & Shi, L. (2019). Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis. Molecular Medicine Reports, 20, 2657-2666. https://doi.org/10.3892/mmr.2019.10494
MLA
Wang, S., Li, L., Shi, L."Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis". Molecular Medicine Reports 20.3 (2019): 2657-2666.
Chicago
Wang, S., Li, L., Shi, L."Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis". Molecular Medicine Reports 20, no. 3 (2019): 2657-2666. https://doi.org/10.3892/mmr.2019.10494